Overview
- Deepinder Goyal publicly answered doctors on Thursday by saying Temple is not a scam, that the project has cost about $30 million with $20 million of his own money, and that pre-prints and independent studies are coming.
- Temple opened pre-orders on November 1 at ₹85,000 for made‑to‑order units and says shipping will begin in early 2027, with a 14‑day no‑questions return policy for buyers.
- Multiple physicians have argued the sensor’s forehead placement over the superficial temporal artery can only measure scalp or facial blood flow and does not by itself prove intracerebral blood flow is being tracked.
- The company frames Temple as a wellness and research wearable rather than a regulated medical device, and it points to internal R&D, a $54 million seed round and an acquisition of Longevous as support for its work.
- The key next step is real‑world validation: shipping to users in early 2027 is likely to produce independent tests and peer‑reviewable data that doctors say are needed to confirm or refute Temple’s headline claims.